Benzinga | Sep 9, 2021 07:04AM EDT

Precision BioSciences And iECURE Announce License And Collaboration Agreement To Develop ARCUS-Based Gene Editing Therapies

iECURE to License Precision's PCSK9-Directed ARCUS Nuclease and Pursue Four Gene Insertion Programs Focused on Liver Diseases; Precision Retains Rights Across All Indications Except Those Licensed to iECURE

iECURE Expects to File a Clinical Trial Application as Early as 2022 for Precision's PBGENE-PCSK9 Candidate for Familial Hypercholesterolemia

Preclinical Data for ARCUS-Mediated Gene Insertion to be Presented Today by iECURE Chief Scientific Advisor, James M. Wilson, M.D., Ph.D. at Precision's Gene Editing R&D Event